Marksans Pharma Limited (NSE:MARKSANS)

Marksans Pharma Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	4,179	3,806	3,137	2,663	1,868
Depreciation & Amortization	986.32	830.02	740.55	518.53	447.76
Other Amortization	-	3.84	2.15	-	-
Loss (Gain) From Sale of Assets	0.64	0.33	-0.94	2.64	-
Loss (Gain) From Sale of Investments	16.98	33.12	-43.63	108.02	-56.23
Stock-Based Compensation	33.38	-	-	-	-
Provision & Write-off of Bad Debts	218.58	83.28	51.57	143.61	26.32
Other Operating Activities	-229.08	-281.96	-320.71	52.89	-186.4
Change in Accounts Receivable	-313.9	-777.9	-371.67	-275.18	-1,039
Change in Inventory	-387.25	-1,955	-1,127	-448.5	-178.49
Change in Accounts Payable	-	-	-	-	284.79
Change in Other Net Operating Assets	76.58	324.83	236.48	-390.97	-173.98
Operating Cash Flow	4,581	2,067	2,304	2,374	992.57
Operating Cash Flow Growth	121.68%	-10.30%	-2.95%	139.19%	-44.42%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-1,305	-1,729	-2,088	-536.31	-463.3
Sale of Property, Plant & Equipment	9.77	12.49	8.54	3.77	0.34
Cash Acquisitions	-	-	-	-266.1	-
Investment in Securities	-1,450	269.87	-259.48	-1	-428.55
Other Investing Activities	262.47	956.74	930.92	-1,792	47.6
Investing Cash Flow	-2,483	-490.09	-1,408	-2,592	-843.91

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Issued	65.06	-	-	52.96	225.52
Total Debt Issued	65.06	-	-	52.96	225.52
Short-Term Debt Repaid	-	-60.06	-124.97	-	-
Long-Term Debt Repaid	-383.96	-295.65	-284	-207.73	-155.17
Total Debt Repaid	-383.96	-355.71	-408.97	-207.73	-155.17
Net Debt Issued (Repaid)	-318.9	-355.71	-408.97	-154.77	70.35
Repurchase of Common Stock	-	-	-	-321.14	-
Common Dividends Paid	-362.53	-271.9	-226.58	-101.71	-105.83
Dividends Paid	-362.53	-271.9	-226.58	-101.71	-105.83
Other Financing Activities	-27.85	-23.85	-51.72	2,606	830.59
Financing Cash Flow	-709.28	-651.46	-687.27	1,978	795.11

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	-5.79	-	-	0.02	-
Net Cash Flow	1,384	925.09	208.4	1,760	943.77

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	3,276	337.45	215.69	1,838	529.27
Free Cash Flow Growth	870.81%	56.45%	-88.26%	247.24%	-59.95%
Free Cash Flow Margin	11.10%	1.29%	0.99%	9.92%	3.55%
Free Cash Flow Per Share	7.23	0.74	0.48	4.42	1.29
Levered Free Cash Flow	703.47	-725.4	-510.23	661.16	-227.75
Unlevered Free Cash Flow	854.25	-652.53	-440.21	699.26	-191.87

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	27.85	23.85	51.72	60.66	80.96
Cash Income Tax Paid	1,397	1,259	1,223	630.14	728.59
Change in Working Capital	-624.57	-2,408	-1,262	-1,115	-1,107

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 1, 2026

Data Sources Report a data error